False-positive findings on dopamine transporter SPECT due to therapeutic dextroamphetamine and amphetamine

Joseph A. Frankl, Sudeshna C Bose, Phillip H Kuo

Research output: Contribution to journalArticle

1 Scopus citations


Dopamine transporter SPECT is an accurate adjunct to clinical evaluation for Parkinson disease when the diagnosis is difficult. Dopaminergic medications may significantly affect dopamine transporter availability and, thus, uptake of dopamine transporter tracers. A patient had a false-positive dopamine transporter SPECT result while she was taking dextroamphetamine and amphetamine for attention-deficit hyperactivity disorder. The SPECT findings normalized after amphetamine therapy was withheld. An accurate medication history combined with knowledge of drugs that interfere with dopamine transporter imaging is critical to ensure accuracy.

Original languageEnglish (US)
Pages (from-to)149-150
Number of pages2
JournalJournal of Nuclear Medicine Technology
Issue number2
Publication statusPublished - Jun 1 2018



  • Amphetamine
  • Dopamine transporter
  • Ioflupane
  • Parkinson disease
  • Single-photon positron emission tomography

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology
  • Radiology Nuclear Medicine and imaging

Cite this